How To Get A ‘Great Britain’ Drug Approval In 2021
New Guidance Attempts To Explain Complexities Of Post-Brexit Regulation
So much will change on the regulatory front next year that the UK drug regulator, the MHRA, has had to issue dozens of new guidance documents to help pharma and biotech firms navigate the new requirements and assessment routes. A key consideration is how the UK will handle centralized EU applications that are still pending on 31 December.
